Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Allergy and Asthma Reports
Published in: Current Allergy and Asthma Reports 11/2014

01-11-2014 | ASTHMA (WJ CALHOUN AND SP PETERS, SECTION EDITORS)

Critical Review of Bronchial Thermoplasty: Where Should It Fit into Asthma Therapy?

Authors: Ajay Sheshadri, Matthew McKenzie, Mario Castro

Published in: Current Allergy and Asthma Reports | Issue 11/2014

Login to get access

Abstract

Bronchial thermoplasty is a device-based therapy for treatment of severe refractory asthma that uses radiofrequency energy to reduce airway smooth muscle and decrease bronchoconstriction. BT improves quality of life and decreases the rate of severe exacerbations with no known major long-term complications. The effectiveness of bronchial thermoplasty persists at least 5 years after the treatment is completed. Further investigation is needed to better define the specific subpopulation of patients with severe asthma who would best benefit from this treatment.
Literature
1.
World health organization (who). Asthma fact sheet no. 207. 2011.
2.
Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, health care use, and mortality in the United States. NCHS data brief. 2012;2012:1–8.
3.
Barnett SB, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007. The Journal of allergy and clinical immunology. 2011;127:145–52.PubMedCrossRef
4.
Smith DH, Malone DC, Lawson KA, et al. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med. 1997;156:787–93.PubMedCrossRef
5.
Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. The Journal of allergy and clinical immunology. 2007;119:405–13.PubMedCrossRefPubMedCentral
6.
Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. The Journal of allergy and clinical immunology. 2003;111:1212–8.PubMedCrossRef
7.
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2014;43:343–73.CrossRef
8.
Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181:315–23.PubMedCrossRefPubMedCentral
9.
10.
Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994;344:219–24.PubMedCrossRef
11.
Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 2003;58:211–6.PubMedCrossRefPubMedCentral
12.
Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA : the journal of the American Medical Association. 1996;275:931–6.CrossRef
13.
Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med. 1993;119:1059–66.PubMedCrossRef
14.
Berger W, De Chandt MT, Cairns CB. Zileuton: Clinical implications of 5-lipoxygenase inhibition in severe airway disease. Int J Clin Pract. 2007;61:663–76.PubMedCrossRef
15.
Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. The Journal of allergy and clinical immunology. 2001;108:184–90.PubMedCrossRef
16.
Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): innovate. Allergy. 2005;60:309–16.PubMedCrossRef
17.
Garcia G, Magnan A, Chiron R, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest. 2013;144:411–9.PubMedCrossRef
18.
Wu AC, Paltiel AD, Kuntz KM, et al. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. The Journal of allergy and clinical immunology. 2007;120:1146–52.PubMedCrossRefPubMedCentral
19.
20.•
James AL, Elliot JG, Jones RL. Airway smooth muscle hypertrophy and hyperplasia in asthma. Am J Respir Crit Care Med. 2012;185:1058–64. Hyperplasia of airway smooth muscle (ASM) cells occurs in both small and large airways in fatal asthma, whereas hypertrophy occurs in ASM cells of the large airways in both fatal and non-fatal asthma.PubMedCrossRef
21.
James AL, Pare PD, Hogg JC. The mechanics of airway narrowing in asthma. The American review of respiratory disease. 1989;139:242–6.PubMedCrossRef
22.
Cohen L, Xueping E, Tarsi J. Epithelial cell proliferation contributes to airway remodeling in severe asthma. Am J Respir Crit Care Med. 2007;176:138–45.PubMedCrossRefPubMedCentral
23.
Panettieri Jr RA, Kotlikoff MI, Gerthoffer WT, et al. Airway smooth muscle in bronchial tone, inflammation, and remodeling: basic knowledge to clinical relevance. Am J Respir Crit Care Med. 2008;177:248–52.PubMedCrossRefPubMedCentral
24.
Danek CJ, Lombard CM, Dungworth DL, et al. Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs. J Appl Physiol. 2004;97:1946–53.PubMedCrossRef
25.
Brown RH, Wizeman W, Danek C, et al. Effect of bronchial thermoplasty on airway distensibility. The European respiratory journal. 2005;26:277–82.PubMedCrossRef
26.
Brown RH, Wizeman W, Danek C, et al. In vivo evaluation of the effectiveness of bronchial thermoplasty with computed tomography. J Appl Physiol. 2005;98:1603–6.PubMedCrossRef
27.
Cox PG, Miller J, Mitzner W, et al. Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations. The European respiratory journal. 2004;24:659–63.PubMedCrossRef
28.
Du Rand IA, Blaikley J, Booton R, et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax. 2013;68(1):i1–i44.PubMedCrossRef
29.
Miller JD, Cox G, Vincic L, et al. A prospective feasibility study of bronchial thermoplasty in the human airway. Chest. 2005;127:1999–2006.PubMedCrossRef
30.
Cox G, Miller JD, McWilliams A, et al. Bronchial thermoplasty for asthma. Am J Respir Crit Care Med. 2006;173:965–9.PubMedCrossRef
31.
Cox G, Thomson NC, Rubin AS, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med. 2007;356:1327–37.PubMedCrossRef
32.
Juniper EF, O’Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. The European respiratory journal. 1999;14:902–7.PubMedCrossRef
33.
Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47:76–83.PubMedCrossRefPubMedCentral
34.
Pavord ID, Cox G, Thomson NC, et al. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med. 2007;176:1185–91.PubMedCrossRef
35.
Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181:116–24.PubMedCrossRefPubMedCentral
36.
Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol. 1994;47:81–7.PubMedCrossRef
37.••
Pavord ID, Thomson NC, Niven RM. Safety of bronchial thermoplasty in patients with severe refractory asthma. Annals of Allergy, Asthma & Immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2013;111:402–7. This study shows 5-year safety and efficacy data relating to subjects that underwent bronchial thermoplasty; the 5-year data also showed no deterioration in lung function.CrossRef
38.••
Wechsler ME, Laviolette M, Rubin AS. Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma. The Journal of allergy and clinical immunology. 2013;132:1295–302. This study concluded that 5 years after the AIR2 trial, there was a significant decrease in severe exacerbations and ED visits by bronchial thermoplasty subjects.PubMedCrossRef
39.
Grenier P, Mourey-Gerosa I, Benali K, et al. Abnormalities of the airways and lung parenchyma in asthmatics: CT observations in 50 patients and inter- and intraobserver variability. Eur Radiol. 1996;6:199–206.PubMedCrossRef
40.
Schatz M, Zeiger RS, Mosen D, et al. Asthma-specific quality of life and subsequent asthma emergency hospital care. The American journal of managed care. 2008;14:206–11.PubMed
41.
Global Initiative for Asthma. Global strategy for asthma management and prevention: Updated 2014. National Institutes of Health 2014.
42.
Niimi A, Matsumoto H, Amitani R, et al. Airway wall thickness in asthma assessed by computed tomography. Relation to clinical indices. Am J Respir Crit Care Med. 2000;162:1518–23.PubMedCrossRef
43.
Park SW, Park JS, Jeong SH, et al. Air trapping is a major determinant of persistent airway obstruction in asthmatics. Respir Med. 2012;106:786–93.PubMedCrossRef
44.
Sarikonda KS, Sheshadri A, Koch T et al. Predictors of bronchial thermoplasty response in patients with severe asthma. American journal of respiratory and critical care medicine 2014; A2429.
45.
Bender B, Milgrom H, Rand C. Nonadherence in asthmatic patients: is there a solution to the problem? Annals of Allergy, Asthma & Immunology : official publication of the American College of Allergy, Asthma, & Immunology. 1997;79:177–85. quiz 185–176.CrossRef
Metadata
Title
Critical Review of Bronchial Thermoplasty: Where Should It Fit into Asthma Therapy?
Authors
Ajay Sheshadri
Matthew McKenzie
Mario Castro
Publication date
01-11-2014
Publisher
Springer US
Published in
Current Allergy and Asthma Reports / Issue 11/2014
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-014-0470-4

Other articles of this Issue 11/2014

Current Allergy and Asthma Reports 11/2014 Go to the issue

OTITIS (DP SKONER, SECTION EDITOR)

Role of Obesity in Otitis Media in Children

ALLERGIC SKIN DISEASES (L FONACIER, SECTION EDITOR)

Hand Dermatitis: an Allergist’s Nightmare

Pediatric Allergy and Immunology (JM Portnoy and CE Ciaccio, Section Editors)

Empowering the Child and Caregiver: Yellow Zone Asthma Action Plan

IMMUNOTHERAPY AND IMMUNOMODULATORS (L COX, SECTION EDITOR)

Immune Mechanisms of Sublingual Immunotherapy

ANAPHYLAXIS AND DRUG ALLERGY (DA KHAN AND M CASTELLS, SECTION EDITORS)

Penicillin and Beta-Lactam Allergy: Epidemiology and Diagnosis

OTITIS (DP SKONER, SECTION EDITOR)

Does the Type of Rhinitis Influence Development of Otitis Media with Effusion in Children?